00:00:00Introduction
00:01:33First-Line Treatment
00:20:36Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy
ÜBER DIESE EPISODE
Englisch
Vereinigte Staaten
NOTIZEN ANZEIGEN 🔗
TRANSKRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
VERGANGENE FOLGEN SUCHEN
Vorhandene Folgen von Oncology Today with Dr Neil Love durchsuchen.
WEITERE EPISODEN IN DIESEM PODCAST
Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)
Ovarian Cancer (2:22)
Endometrial Cancer (37:48)
CME information and select publications
Featuring an interview with Professor Nicoletta Colombo, including the following topics:
Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)
Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)
Definition…
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:
Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzum…
Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)
First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)
Management of HER2-Positive Gastroesophageal Cancer (25:11)
Neoadjuvant Thera…
Featuring an interview with Dr Alexander E Drilon, including the following topics:
Overview of targetable biomarkers in lung cancer (0:00)
Biomarker testing for genomic alterations in lung cancer (5:24)
Overview of ROS1 alterations in lung cancer (13:44)
Efficacy data with ROS1 inhibitors for lung…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von Dr. Neil Love, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
BEARBEITEN
Vielen Dank, dass Sie uns helfen, die Podcast-Datenbank auf dem neuesten Stand zu halten.
